| Bid | 6 |
| Market Cap | 1.53B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -3.58 |
| PE Ratio (ttm) | -4.19 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 15.88 |
| Volume | 1,696,454 |
| Avg. Volume (20D) | 1,136,560 |
| Open | 15.75 |
| Previous Close | 15.29 |
| Day's Range | 14.87 - 15.90 |
| 52-Week Range | 14.79 - 47.45 |
| Beta | undefined |
About DYN
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therape...
Analyst Forecast
According to 10 analyst ratings, the average rating for DYN stock is "Buy." The 12-month stock price forecast is $51, which is an increase of 240.00% from the latest price.
2 months ago · seekingalpha.com
Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle DiseasesDyne Therapeutics, Inc. develops treatments for muscle diseases using its FORCE platform, with promising candidates DYNE-101 and DYNE-251 targeting DM1 and DMD, respectively. DYNE-251 shows significan...